Sector Gamma AS Buys Shares of 148,147 United Therapeutics Co. (NASDAQ:UTHR)

Sector Gamma AS bought a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 148,147 shares of the biotechnology company’s stock, valued at approximately $11,815,000. United Therapeutics comprises about 2.0% of Sector Gamma AS’s investment portfolio, making the stock its 19th largest holding. Sector Gamma AS owned 0.34% of United Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Pearl River Capital LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $32,000. Private Ocean LLC purchased a new stake in shares of United Therapeutics during the second quarter worth about $34,000. NEXT Financial Group Inc grew its stake in shares of United Therapeutics by 72.7% during the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 200 shares during the last quarter. Quadrant Capital Group LLC grew its stake in shares of United Therapeutics by 61.2% during the third quarter. Quadrant Capital Group LLC now owns 661 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 251 shares during the last quarter. Finally, Machina Capital S.A.S. grew its stake in shares of United Therapeutics by 776.4% during the second quarter. Machina Capital S.A.S. now owns 964 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 854 shares during the last quarter. Institutional investors own 94.19% of the company’s stock.

NASDAQ:UTHR traded up $0.98 during trading hours on Friday, reaching $91.61. The company had a trading volume of 269,700 shares, compared to its average volume of 531,029. The business’s 50 day moving average price is $83.92 and its 200-day moving average price is $83.94. United Therapeutics Co. has a 1-year low of $74.31 and a 1-year high of $128.94. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.11 and a quick ratio of 3.91. The firm has a market cap of $4.02 billion, a PE ratio of 6.84 and a beta of 0.97.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.34 by $0.82. The firm had revenue of $401.50 million for the quarter, compared to analyst estimates of $342.28 million. United Therapeutics had a negative return on equity of 3.54% and a negative net margin of 6.04%. United Therapeutics’s revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.98 EPS. On average, analysts expect that United Therapeutics Co. will post -0.96 earnings per share for the current fiscal year.

A number of research firms recently commented on UTHR. ValuEngine raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 29th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Cowen set a $118.00 target price on United Therapeutics and gave the stock a “hold” rating in a report on Friday, September 13th. Wedbush reaffirmed a “buy” rating and set a $273.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH raised United Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $103.00 to $106.00 in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. United Therapeutics has a consensus rating of “Buy” and a consensus target price of $120.30.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Read More: What is a dividend reinvestment plan?

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply